Clinical Trials

Central Nervous System Neoplasms

NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

108 enrolled 14 charts

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT01201850 2021-05-19

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Phase NA Terminated

7 enrolled 8 charts

Central Nervous System Neoplasms

NCT01013285 2020-09-21

Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

70 enrolled 18 charts

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00337207 2020-02-07

Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

55 enrolled 10 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Phase 1/2 Terminated

12 enrolled 7 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00720356 2018-10-26

Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

115 enrolled 11 charts

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00621686 2018-05-08

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

54 enrolled 8 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00501891 2013-05-27

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

32 enrolled 8 charts